Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia

Leukemia Research

Volumn 33, Issue 8, 2009, Pages 1072-1078

  Montillo, Marco ^a   Ricci, Francesca ^a   Tedeschi, Alessandra ^a   Cafro, Anna Maria ^a   Nosari, Anna Maria ^a   Nichelatti, Michele ^a   Marbello, Laura ^a   Morra, Enrica ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

ATRA; Fludarabine Ara C; Minimum dose fludarabine; Refractory relapsed AML

Indexed keywords

CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; BACTERIAL PNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; FEMALE; FOLLICULITIS; GASTROINTESTINAL INFECTION; HIDRADENITIS; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOBACTERIOSIS; MYCOSIS; NAUSEA; NEUTROPENIA; NON PROMYELOCYTIC ACUTE GRANULOCYTIC LEUKEMIA; PRIORITY JOURNAL; SALVAGE THERAPY; SEPSIS; SKIN INFECTION; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UROGENITAL TRACT INFECTION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE; TRETINOIN; VIDARABINE;

EID: 67349147515     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.12.014     Document Type: Article

References (62)

1. Robak T., and Wrzesien-Kus A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma 43 (2002) 281-291
2. Lowenberg B., Downing J.R., and Burnett A. Acute myeloid leukemia. N Engl J Med 341 (1999) 1051-1062
3. Kern W., Schoch C., Haferlach T., Braess J., Unterhalt M., Wörmann B., et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 14 (2000) 226-231
4. Breems D.A., Van Putten W.L., and Huijgens P.C. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23 (2005) 1969-1978
5. Herzig R.H., Lazarus H.M., and Wolff S.N. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 3 (1985) 992-997
6. Hiddemann W., Kreutzmann H., Straif K., Ludwig W.D., Mertelsmann R., Planker M., et al. High dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 14 Suppl. 2 (1987) 73-77
7. Amadori S., Arcese W., Isacchi G., Meloni G., Petti M.C., Monarca B., et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 9 (1991) 1210-1214
8. Estey E., Thall P., Andreeff M., Beran M., Kantarjian H., O'Brien S., et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12 (1994) 671-678
9. Visani G., Tosi P., Zinzani P.L., Manfroi S., Ottaviani E., Testoni N., et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of "Poor Risk" acute myeloid leukemias. Leukemia 8 (1994) 1842-1846
10. Clavio M., Carrara P., Miglino M., Pierri I., Canepa L., Balleari E., et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 81 (1996) 513-520
11. Nokes T.J., Johnson S., Harvey D., and Goldstone A.H. FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes. Leuk Lymphoma 27 (1997) 93-101
12. Parker J.E., Pagliuca A., Mijovic A., Cullis J.O., Czepulkowski B., Rassam S.M., et al. Fludarabine, cytosine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 99 (1997) 939-944
13. Montillo M., Mirto S., Petti M.C., Latagliata R., Magrin S., Pinto A., et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 58 (1998) 105-109
14. Steinmetz H.T., Schulz A., Staib P., Scheid C., Glasmacher A., Neufang A., et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol 78 (1999) 418-425
15. Ferrara F., Melillo L., Montillo M., Leoni F., Pinto A., Mele G., et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. Ann Hematol 78 (1999) 380-384
16. Jackson G., Taylor P., Smith G.M., Marcus R., Smith A., Chu P., et al. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 112 (2001) 127-137
17. Virchis A., Koh M., Rankin P., Mehta A., Potter M., Hoffbrand A.V., et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol 124 1 (2004) 26-32
18. Estey E., Plunkett W., Gandhi V., Rios M.B., Kantarjian H., and Keating M.J. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 9 (1993) 343-350
19. Gandhi V., and Plunkett W. Modulation of arabinosyl nucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 48 (1988) 329-334
20. Gandhi V., Estey E.H., Keating M.J., and Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11 (1993) 116-124
21. Tosi P., Visani G., Ottaviani E., Manfori S., Zinzani P.L., and Tura S. Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 8 (1994) 2076-2082
22. Gandhi V., Estey E., Du M., Keating M.J., and Plunkett W. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res 3 (1997) 1539-1545
23. Estey E.H., Keating M.J., McCredie K.B., Freireich E.J., and Plunkett W. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 4 (1990) 95-99
24. Tafuri A., and Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4 (1990) 826-834
25. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 (1988) 567-572
26. Warrell R.P., Frankel S.R., Miller W.H., Scheinberg D.A., Itri L.M., Hittelman W.N., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324 (1991) 1385-1393
27. Sacchi S., Terzi A., Vanzanelli P., et al. Bcl-2 and adhesion molecule modulation induced by ATRA in non M3 blast cultures. Haematologica 81 (1996) 30
28. Miyashita T., and Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81 (1993) 151
29. Hu Z.B., Yang G.S., Li M., Miyamoto N., Minden M.D., and McCulloch E.A. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals. Leukemia 9 (1995) 789
30. Kaufamann S.H., Karp J.E., Svingen P.A., Krajewski S., Burke P.J., Gore S.D., et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 91 (1998) 991-1000
31. Venditti A., Stasi R., Del Poeta G., Buccisano F., Aronica G., Bruno A., et al. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of "poor prognosis" acute myeloid leukemia. Leukemia 9 (1995) 1121-1125
32. Seiter K., Feldman E.J., Halicka H.D., Deptala A., Traganos F., Burke H.B., et al. Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukaemia. Br J Haematol 108 (2000) 40-47
33. Belhabri A., Thomas X., Wattel E., Chelghoum Y., Anglaret B., Vekhoff A., et al. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukema: a phase II randomized trial. Hematol J 3 (2002) 49-55
34. Estey E.H., Thall P.F., Pierce S., Cortes J., Beran M., Kantarjian H., et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93 (1999) 2478-2484
35. Bishop J.F., Young G.A., Szer J., et al. Randomized trial of high dose cytosine arabinoside (Ara-C) combination in induction in acute myeloid leukemia (AML). Proc Am Soc Clin Oncol 11 (1992) 849
36. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 7 (1998) 2322-2333
37. Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloomfield C.D., et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8 (1990) 813-819
38. World Health Organization. A handbook for reporting results of cancer treatment (1979), WHO Publication, Geneva
39. Leopold L.H., and Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 43 (2002) 1715-1727
40. Rees J.K., Gray R.G., Swirsky D., and Hayhoe F.G. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 2 (1986) 1236-1241
41. Keating M.J., Kantarjian H., Smith T.L., Estey E., Walters R., Andersson B., et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7 (1989) 1071-1080
42. Thalhammer F., Geissler K., Jager U., Kyrle P.A., Pabinger I., Mitterbauer M., et al. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol 72 (1996) 216-222
43. Craddock C., Tauro S., Moss P., and Grimwade D. Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 129 (2005) 18-34
44. Tosi P., Visani G., Ottaviani E., Pellacani A., Manfroi S., and Tura S. Retinoids increase idarubicin cytotoxicity in human myeloid leukemia cell lines. Anticancer Drugs 7 (1996) 774-779
45. Campos L., Rouault J.P., Sabido O., Oriol P., Roubi N., Vasselon C., et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81 (1993) 3091-3096
46. Pallis M., Zhu Y.M., and Russell N.H. Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression. Leukemia 11 (1997) 945-949
47. Ong Y.L., McMullin M.F., Bailie K.E., Lappin T.R., Jones F.G., and Irvine A.E. High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br J Haematol 111 (2000) 182-189
48. Del Poeta G., Venditti A., Del Principe M.I., Maurillo L., Buccisano F., Tamburini A., et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 101 (2003) 2125-2131
49. Marcucci G., Byrd J.C., Dai G., Klisovic M.I., Kourlas P.J., Young D.C., et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101 (2003) 425-432
50. Bradbury D.A., Aldington S., Zhu Y.M., and Russell N.H. Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br J Haematol 94 (1996) 671-675
51. Yang G.S., Minden M.D., and McCulloch E.A. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. Leukemia 8 (1994) 2065-2075
52. Milligan D.W., Wheatley K., Littlewood T., Craig J.I., Burnett A.K., and NCRI Haematological Oncology Clinical Studies Group. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 107 (2006) 4614-4622
53. Carella A.M., Cascavilla N., Greco M.M., Melillo L., Sajeva M.R., Ladogana S., et al. Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study. Leuk Lymphoma 40 (2001) 295-303
54. Huhmann I.M., Watzke H.H., Geissler K., Gisslinger H., Jäger U., Knöbl P., et al. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol 73 (1996) 265-271
55. Ross D.D., Doyle L.A., Yang W., Tong Y., and Cornblatt B. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochem Pharmacol 50 (1995) 1673-1683
56. Anderlini P., Benjamin R.S., Wong F.C., Kantarjian H.M., Andreeff M., Kornblau S.M., et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 13 (1995) 2827-2834
57. Pastore D., Specchia G., Carluccio P., Liso A., Mestice A., Rizzi R., et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Ann Hematol 82 (2003) 231-235
58. Wrzesien-Kus A., Robak T., Wierzbowska A., Lech-Marańda E., Pluta A., Wawrzyniak E., et al. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol 84 (2005) 557-564
59. Lowenberg B., and Touw I.P. Hematopoietic growth factors and their receptors in acute leukemia. Blood 81 (1993) 281-292
60. Ferrara F., Di Noto R., Viola A., Russo C., Boccuni P., Costantini S., et al. Complete remission in acute myeloid leukaemia with t(8;21) following treatment with G-CSF: flow cytometric analysis of in vivo and in vitro effects on cell maturation. Br J Haematol 106 (1999) 520-523
61. Weltermann A., Fonatsch C., Haas O.A., Greinix H.T., Kahls P., Mitterbaue G., et al. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia 18 (2004) 293-302
62. Keating M.J., Estey E., Plunkett W., Iacoboni S., Walters R., Kantarjian H., et al. Evolution of clinical studies with high dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol 12 (1985) 98-104